APPLIED STEMCELL
Founded in 2008 to provide industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) and gene editing, Applied StemCell continues to use our innovative technologies to power the discovery and development of advanced therapeutics. Our products and services enable the full spectrum of basic research to early-stage GMP manufacturing—including disease modeling, iPSC services, library construction, drug screening, and nonclinical and pre-IND studies—and our patented technologies ensure a clear IP path to commercialization.
INDUSTRY INSIGHTS
-
![Getting Cell therapies To IND Faster]( "The Advantages Of Off-The-Shelf GMP iPSCs With A DMF")
The Advantages Of Off-The-Shelf GMP iPSCs With A DMFLearn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.
-
![GettyImages-1347856192-plasmid-dna-development-research-lab]( "Efficient Mammalian Cell Engineering For Difficult Protein Expression In 4-6 Weeks")
Efficient Mammalian Cell Engineering For Difficult Protein Expression In 4-6 WeeksBy leveraging cells equipped with an existing TARGATT™ landing pad, we demonstrate how inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.
-
![Beyond CRISPR]( "Beyond CRISPR: Next-Gen Gene Editing With TARGATT, Mad7, Base Editing")
Beyond CRISPR: Next-Gen Gene Editing With TARGATT, Mad7, Base EditingConsider several gene editing technologies — TARGATT, Mad7, and Base Editing — and gain insights into their transformative applications in genetic engineering and therapeutic development.
-
![The Future Of Allogeneic Cell Therapy]( "The Future Of Allogeneic Cell Therapy: Hypoimmunogenic Donor Cells")
The Future Of Allogeneic Cell Therapy: Hypoimmunogenic Donor CellsExplore how TARGATT® gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.
CONTACT INFORMATION
Applied StemCell
521 Cottonwood Dr Suite 111
Milpitas, CA 95035
UNITED STATES
Phone: (408) 773-8007
Contact: A. Pia Abola, Ph.D., Director of Marketing
SOLUTIONS
-
![GettyImages-1356994439-stem-cell-DNA-gene-editing-tweezers]( "ActiCells™ RUO Hypo hiPSCs")
Accelerate your allogeneic development by starting with a hypoimmunogenic iPSC platform reprogrammed from CD34+ cord blood cells.
-
![GettyImages-1493118778 blood, cell therapy]( "ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-In Kit")
Rapidly advance your allogeneic development with a hypoimmunogenic iPSC platform that has pre-built TARGATT™ large knock-in technology.
-
![GettyImages-1316503044-dna-strand-double-helix-gene-editing]( "iPSC Gene Editing Services")
From precise edits to robust expression, get iPSC genome editing done right — from the experienced innovators in gene editing and iPSC technology.
-
![GettyImages-533059254-rna-dna-strand-light]( "Overcome CRISPR's Limitations With TARGATT™ Gene Knock-In Technology")
Build the most relevant cell line for your studies with the ability to insert 20+ kb of DNA site specifically, in single copy, and at efficiencies approaching 100% after selection.
-
![GettyImages-1349793348 DNA]( "Quality GMP-Grade iPSC And Knockin-Ready TARGATT™ iPSC")
To jump start iPSC derived therapeutic cell product development; achieve reliable and efficient genome integration with our innovative solutions.
-
![genetic engineering gene manipulation--GettyImages-667138650]( "Gene Editing Services")
Choose from our different technology platforms or ask our scientists to customize a project to achieve your goals. We’ll use our patented and proprietary technologies, such as our Rapid Automated Cell Line Editing (RACE™) protocol, to ensure quality, accuracy, and fast turnaround times.
